ERN1 and neoplasm: Since IRE1α and PERK can respond to therapy-induced stress by triggering pro-tumor proliferative signals or anti-tumor apoptotic signals, there is an unmet need for patient stratification and personalized biomarker development when incorporating UPR inhibitors into clinical workflows and treatment paradigms.